Little is known about long non-coding RNA (lncRNA) related to innate immunity in lung cancer. The advanced glycosylation end-product specific receptor (AGER) belongs to the immunoglobulin superfamily, and currently, is the only innate immune pattern-recognition receptor whose abnormal expression has been detected in lung cancer. We aimed to explore the lncRNA that is related to AGER and test its effect on lung carcinogenesis. We selected one lncRNA whose chromosome location is in close proximity to AGER namely lnc-AGER-1 (defined as lncAGER). The expression of lncAGER was tested in 276 pairs of lung cancer tissues and adjacent lung normal tissues, and its correlation with lung cancer clinical progress was analyzed. A series of assays were further used to assess the biological function of lncAGER on lung cancer development, tumor immunity and autophagy.
However, there is still a great need for alternative treatment strategies for treating lung cancer, as the 5-years' survival rate is below 20%. Immunotherapy is currently a white hope for oncotherapy, yet emerging data suggests that the immuno checkpoint inhibitors such as programmed death 1 (PD-1)/programmed death ligand 1 (PD-1/PD-L1) inhibitors show promise towards improving the survival time of lung cancer patients. [4] [5] [6] The Food and Drug Administration (FDA) have approved two anti-PD-1 monoclonal antibodies for treating lung cancer, however in response to the therapy, resistance to the drugs has increasingly been observed. 7, 8 Thus, further studies towards understanding the role of immunity in lung cancer are warranted, given that limited studies in the area have been undertaken as lung cancer was historically recognized as a non-immunogenic disease. Finding critical molecules that modulate immunity in the context of lung carcinogenesis would lead to the exploitation of immunotherapeutic agents.
The innate immune system provides the first line of protection against infectious and non-infectious tissue injury. Environmental carcinogens such as tobacco can induce lung tissue injury and trigger the activation of innate immune system through pattern-recognition receptors (PPRs) including Toll-like receptors (TLRs) and advanced glycosylation end-product specific receptor (AGER, also named receptor for advanced glycation end products, RAGE). 9 AGER can recognize endogenous molecules released during chronic inflammation, a major contributing factor to the pathogenesis of lung cancer.
Notably, it has been shown that pulmonary AGER is required for allergen-induced innate lymphoid cells accumulation in the lung. 10 Further, AGER is one of a limited number of pathogen-recognition receptors whose expression is altered in lung cancer. 11, 12 Meanwhile, analyzing the public data of lung cancer cohorts namely GSE32863
(https://www.ncbi.nlm.nih.gov/geo/geo2r/?acc=GSE32863), and GS E27262 (https://www.ncbi.nlm.nih.gov/geo/geo2r/?acc= GSE27262) using the GEO2R software, AGER ranks among the top five abnormal coding genes in lung cancer. But for TLRs, their expressions are normal.
Accumulating evidences show that long non-coding RNAs (lncRNAs), non-protein coding transcripts longer than 200 nucleotides, are crucial epigenetic regulators of protein expression and function.
Numerous lncRNAs have been identified as being associated with lung cancer. 13, 14 These lncRNAs function as possible oncogenes or tumor suppressors to promote or dampen lung cancer development through several pathological mechanisms such as the epithelial-mesenchymal transition, 15 the MAPK signaling pathway. 16 However, little is known about the role of immunity-related lncRNAs in lung cancer.
In the current study, we aimed to explore whether innate immune related lncRNAs are modulated in the context of lung carcinogenesis. Given that lncRNAs may exert their biological functions via regulation of neighbor protein-coding genes, one lncRNA named lnc-AGER-1 (defined as lncAGER here: http://www. fetal bovine serum (FBS). Cells were placed in a CO 2 incubator (SANYO Electric Co., Ltd., Chuou-ku, Osaka City, Japan) with constant 90% humidity and 5% CO 2 . The lung cells were utilized for lncAGER expression analysis. HEK-293 was used for lentivirus packaging and production and THP-1 was utilized for co-cultivation assays.
| Gene expression detection
The routine SYBR-green quantitative reverse real-time PCR (qRT-PCR) was performed to assess the expression of lncAGER and AGER in the 276 pairs of lung tissues and 13 cases of lung cell lines with β-actin used as an internal standard control. The primers for lncAGER were 5′-AAC CAG GAG GAA GAG GAG GA-3′ (forward) and 5′-TTG GCA AGG TGG GGT TAT AC-3′ (reverse), for AGER were 5′-CTA CCG AGT CCG TGT CTA CC-3′ (forward) and 5′-AGT GTG AAG AGC CCT GTC TC-3′
(forward) and for β-actin were 5′-GGC GGC ACC ACC ATG TAC CCT-3′
(forward) and 5′-AGG GGC CGG ACT CGT CAT ACT-3′ (reverse 
| Demethylation treatment with 5-Aza-CdR
On account of that hypermethylation was found to be associated with decreased expression of AGER in lung cancer tissues, 19 we speculated 
| MicroRNA mimics treatment and luciferase assay
Given that bioinformatics analysis (http://www.mirbase.org/index. 
| Subcellular fractionation
To establish the subcellular localization of lncAGER, cytosolic and nuclear fractions were isolated using the nuclear/cytoplasmic isolation kit (Biovision, San Francisco, CA). Following total RNA extraction from the cytosolic and nuclear fractions, gene expression analysis was performed by the qRT-PCR.
| Tumor cell viability and proliferation assay in vitro
The cell counting kit-8 (CCK8) assay, plate colony and soft-agar colony forming experiments were performed to assess the effect of lncAGER on viability and proliferation of PC9 and L78 cells, in accordance with the manufacturer's protocols. In the CCK8 assay, cells were cultured in
| 307 a 96-well plate with 1000 cells per well and the cell viability was monitored after 24, 48, 72, and 96 h. In the plate colony experiment, the cells were plated in a 6-well plate at a density of 1000 cells each group and cultured for two weeks. After stained with Giemsa, the visible colonies were counted (The whole plate was divided into nine sub-boxes and total clones were counted in settled six representative fields). In the soft-agar experiment, the lower layer agar contained 5 mL of 0.75% low melting agar in RPMI-1640 medium with 10% FBS, while the upper second layer containing 0.35% agar dissolved in RPMI-1640 medium with 10% FBS in a 60 mm dish. When solidified, the upper layer was injected with 1000 cells. After cultured for 3 wk, the dishes were stained with 0.04% crystal violet (Sigma, Guangzhou, China) and the colonies were counted (The whole plate was divided into 16 sub-boxes and total clones were counted in settled eight representative fields). All trials were conducted at least three times.
| Flow cytometry analysis
The flow cytometry analysis was used to establish whether lncAGER had an effect on cell cycle and apoptosis. For cell cycle analysis, PC9
and L78 cell lines were labeled with propidium iodide (PI) (7sea-pharmtech, Shanghai, China). For analysis of apoptosis, the Annexin Vfluorescein isothiocyanate/7-Aminoactinomycin D (FITC/7-AAD) apoptosis kit was used according to the manufacturer's construction (MULTISCIENCES, Hangzhou, China). 
| Tumor cell migration and invasion assay

| Tumor growth in vivo
The PC9 and L78 cell lines were diluted to a concentration of 1 × 10 6 cells/ Percentage of positive cells examined was scored as 0 (negative), 1 (<10%), 2 (11-50%), 3 (51-80%), and 4 (>80%) by two independent pathologists. The relative AGER expression was defined as the intensity score multiplying the percentage score. 
| Autophagy detection
Autophagy is known as programmed type II cell death, which plays an essential role in development, organization, and functions of the immune system. Defects in autophagy lead to several diseases, including cancer and autoimmunity. 22 Here, autophagy level was determined in terms of the ratio between LC3-II protein expression and LC3-I protein expression. The routine western blotting analysis was used to test for the protein expression levels of both LC3-II and LC3-I with Tubulin serving as an interval standard control.
| Statistical analysis
The paired t-test was used to assess the differences in gene expression and frequency of methylation level between lung cancer tissues and adjacent lung normal tissues. The student's t-test and one-way Anova test were applied for analyzing the differences in quantitative data between two groups. The Pearson correlation analysis was performed to analyze correlation between two the quantitative data. All tests were two-sided by using the Stata 12.0 software and P-value less than 0.05 was considered to be statistically significant. bcm.edu/cpat/index.php) strongly suggested that lncAGER has no coding probability. As shown in Figure 1A , the expression of lncAGER was significantly lower in lung cancer tissues when compared to adjacent lung normal tissues in southern samples Figure 1B ). In addition, the lentiviral vector carrying lncAGER was successfully constructed and high expression of lncAGER in both the PC9 and L78 cells was evident ( Figure S1a ). In addition, the expression of AGER was significantly down-regulated in cancer tissues compared to their adjacent normal tissues (P < 0.001;
Figure S1b-d), which are concordant with previously published studies. 11, 12 The demographics and clinical feathers of studied patients are listed in Table 1 .
| LncAGER expression is correlated with T status
The expression status of lncAGER was classified as "High" or "Low" on the basis of whether or not owing to the expression of lncAGER in lung tissues upon in adjacent lung normal tissues. As listed in Table 2 
| Promoter methylation directly contributes to decreased lncAGER but not AGER expression
After treatment of PC9 cells with 5-Aza-CdR, lncAGER expression increased sequentially along with increase of 5-Aza-CdR concentration (P = 0.012; Figure 2F ). A similar trend was observed on AGER expression. However, the effect was not significant (P = 0.704; Figure S3a ). The MassARRAY further showed that cancer tissues harbored a significantly higher methylation level at promoter region of lncAGER than normal tissues ( Figure 2G ). However, no significant difference was observed for AGER ( Figure S3b, c) . Moreover, the average methylation level of lncAGER promoter was negatively correlated with lncAGER expression (P = 0.004; Figure 2H ).
| LncAGER inhibits proliferation and tumor growth of lung cancer cells
Using the CCK8 assay, it was shown that the proliferation of cells expressing lncAGER was significantly lower when compared to the control groups ( Figure 3A) . Similarly, both the plate colony and softagar experiments showed that the up-regulation of lncAGER impaired the tumorigenesis abilities of both the PC9 and L78 cell lines in vitro ( Figures 3B and 3C ). The findings were corroborated with our in vivo work which showed that lncAGER inhibited tumorigenesis in nude mice. As shown in Figure 3D , the tumors were smaller and slower to develop in mice, which were injected with the cells that overexpressed lncAGER when compared to control cells. Meanwhile, the | 311 pathological characteristics of tumor were more obvious in the latter than the former ( Figure 3E ). In addition, the tumor tissues originated from overexpressed lncAGER cells expressed higher AGER than that originated from the control cells ( Figure 3F ).
| LncAGER suppresses cell migration, but not invasion
As shown in Figure 4A , the ability of PC9 cells to migrate was impaired in cells which over-expressed lncAGER (P = 0.026), however, the invasion ability through Matrigel™ remained unchanged when compared to control cells (P = 0.732; Figure 4B ). We failed to detect the ability to migrate and invade of L78 cells because no cells pass through the Boyden chambers.
| LncAGER affects cell cycle and apoptosis
The flow cytometry data showed that the overexpression of lncAGER induced more cells arrest at G0/G1 phase and concomitantly fewer cells at the S phase of cell cycle when compared to control cells ( Figure 4C) . Also, higher rates of apoptosis were evident in cells which overexpressed lncAGER when compared to the control cells ( Figure 4D ). The darker the color represents the higher the methylation rate (left). Methylation level was calculated from 15 pairs of lung cancer and adjacent normal tissues and the frequency refers to the average methylation rate of tumor or normal tissues (right). P-value was calculated by the paired t-test. (H) Correlation between average methylation level of 7 CG sites and lncAGER expression. P-value was calculated by the Spearman rank correlation analysis. *P < 0.05, **P < 0.01, ***P < 0.001
| LncAGER possibly actives autophagy
As AGER has been reported to affect autophagy, 23 herein we asked whether the lncAGER has a similar function. Levels of autophagy, as indicated by an enhanced LC3-II/LC3I ratio, were significantly higher in PC9 and L78 cells which overexpressed lncAGER when compared to the corresponding control cells ( Figure 5A ), suggesting that lncAGER may modulate autophagy in these cells. The CCK8 assay was conducted to determine the proliferation of PC9 and L78 cells co-cultured with THP1. (C) The flow cytometry was conducted to determine the cell apoptosis of PC9 and L78 cells co-cultured with THP1. Bar height corresponds to the mean, and error bars represent SD for three biological or technical replicates. *P < 0.05, **P < 0.01, ***P < 0.001, calculated by the Student's t-test Furthermore, our study suggests that lncAGER may also functionally conduces to cytotoxic activity of immunologic effector cells and promoted autophagy. Importantly, to our knowledge, our study is the first to explore the role on innate-immune related lncRNAs in lung cancer development.
The lncAGER is a 656 bp transcript without protein-coding potency. It is located on chromosome 6p21.32 (chr6:32152516-32153659), 417 bp upstream to the AGER gene. The 6p21.32 is an identified susceptible region of lung cancer in different ethnicities. [24] [25] [26] Accumulation evidences demonstrated that AGER is related to lung cancer, a pathology that is intimately linked with the innate immune system and inflammation. 11, 12 Specifically, it has been shown that AGER is down-regulated or absent during lung carcinogenesis. 11, 12 Further, GEO chip data (GSE32863, GSE27262) showed that AGER ranks among the top five abnormal coding genes in lung cancer.
Further, in contrast as most cancer types wherein AGER expression is up-regulated, [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] in the present study, we also found that AGER was down-regulated in the lung cancer tissues used herein. While AGER is expressed in innate immune cells to enable the recognition of allergens and to active innate immune responses, it is also expressed in epithelial cell such as those which are present in the pulmonary tissue to enable innate immune cells recruitment. 27, 37, 38 Notably, genetic variants in the AGER gene have been reported to be associated with lung cancer risk in a Chinese population. 39, 40 Together, these studies suggest that AGER may play a role in anti-lung oncogenesis.
In the current study, we found that lncAGER exerted an inhibitory action on carcinogenesis, similar to that exhibited by AGER. We found that lncAGER was down-regulated owing to high lever methylation in lung cancer and that the low-expression of lncAGER was correlated with advanced T status. The 5-Aza-CdR treatment could restore lncAGER expression. Hypermethylation in upstream of AGER has been reported to be associated with decreased AGER expression. 19 On account of lncAGER is located at upstream of AGER, based on our findings, we hold the opinion that this hypermethylation first causes reduced lncAGER expression and followed by AGER decrease owing to lncAGER regulation.
Over-expression of lncAGER significantly inhibited cell proliferation of lung cancer cells. LncAGER also induced cell cycle arrest at G0/G1 phase with fewer cells in the S phase, suggesting that lncRNA impairs cell division. Also, we showed that lncAGER promoted cell apoptosis. Specially, ectopic lncAGER expression is sufficient to inhibit migration but not invasion of lung cancer cells.
Unlike migration referring motile ability, cell invasion defines the ability of cells to become motile and to navigate through the extracellular matrix within a tissue or to infiltrate neighbouring tissues. This process needs gene expression changes causing proteolysis and degradation of the matrix, 41 which apparently fail to achieve by lncAGER. Cell invasion is close to cancer metastasis and needs synthesis and secretion of degradation enzymes. This may be why lncAGER expression correlates with T but not N and M in patients. We propose that lncAGER exerts its inhibitory role on lung cancer in part due to effects on AGER. Underlying the ceRNA mechanism, we propose that lncAGER acts as a miR-185 sequestrate and thereby increases the expression of AGER. MiR-185 has been demonstrated to target AGER in esophageal squamous cell carcinomas. 33 Here, miR-185 was consistently found to target on AGER in lung cancer. Controversially, miR-185 is an identified tumor suppressor of several cancers, [42] [43] [44] [45] [46] which has been reported to be involved in chemo-resistance of lung cancer. 17 Further, miR-185 has been discovered to target AKT1 and ABCC1 to inhibit lung genesis and progression. 17, 18 Here, lncAGER also prevents suppression effect of miR-185 on AKT1 and ABCC1 as same as what it had done on AGER, suggesting that lncAGER has reciprocal effect on lung carcinogenesis.
Inconceivably, both AKT1 and ABCC1 were reversely downregulated in ectopic lncAGER cells when compared to control cells. This is really confused but probable. It is plausible to speculate that by sponging other microRNAs or regulatory mechanism, lncAGER might also affect expression of other protein coding genes that may have regulatory effect on AKT1 and ABCC1 expression.
Anyway, our findings confirm that lncAGER exerts an integrated effect playing as an inhibitory role on lung cancer.
In summary, our present study revealed that lncAGER is downregulated in lung cancer. Upregulation of lncAGER can inhibit lung cancer proliferation and migration, induce cell cycle arrest at G 0 /G 1 phase and promote apoptosis. LncAGER also functions in a manner similar to that of its target, AGER, to possibly facilitate tumor immunity and autophagy via up-regulation of AGER by sponging miR-185 ( Figure 6 ). Taken together, these data demonstrate that lncAGER plays an inhibitory role in lung oncogenesis and may be a druggable target or as a drug towards the curtailment of lung cancer.
